MCID: EWN002
MIFTS: 43

Ewing's Family of Tumors malady

Categories: Rare diseases, Neuronal diseases, Bone diseases, Genetic diseases

Aliases & Classifications for Ewing's Family of Tumors

Aliases & Descriptions for Ewing's Family of Tumors:

Name: Ewing's Family of Tumors 50
Neuroectodermal Tumor, Primitive 69
Primitive Neuroectodermal Tumor 50
Ewing Family of Tumors 50
Ewing’s Tumor of Bone 50
Extraosseous Ewing’s 50
Askin’s Tumor 50

Classifications:



Summaries for Ewing's Family of Tumors

MalaCards based summary : Ewing's Family of Tumors, also known as neuroectodermal tumor, primitive, is related to extraosseous ewing's sarcoma and askin's tumor. An important gene associated with Ewing's Family of Tumors is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are GPCR Pathway and PEDF Induced Signaling. The drugs Ritonavir and Darunavir have been mentioned in the context of this disorder. Affiliated tissues include bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cellular

Related Diseases for Ewing's Family of Tumors

Diseases related to Ewing's Family of Tumors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 75)
id Related Disease Score Top Affiliating Genes
1 extraosseous ewing's sarcoma 12.4
2 askin's tumor 12.4
3 supratentorial primitive neuroectodermal tumor 12.4
4 cerebral primitive neuroectodermal tumor 12.3
5 intracranial primitive neuroectodermal tumor 12.2
6 extraosseous ewings sarcoma-primitive neuroepithelial tumor 11.2
7 ewing sarcoma 11.1
8 sarcoma 10.7
9 intracranial sinus thrombosis 10.2 KIT KITLG
10 myotonic dystrophy 1 10.2 EPO KITLG
11 acute canaliculitis 10.2 CDKN2A MTOR
12 parasitic conjunctivitis 10.2 EPO ERBB2
13 pulmonary immaturity 10.1 CDK4 EWSR1 KIT
14 skeletal tuberculosis 10.1 CDKN2A ERBB2
15 gestational choriocarcinoma 10.1 CDK4 EWSR1 KIT
16 diabetes persistent mullerian ducts 10.1 CSF3 EWSR1 FLI1
17 rhabdomyosarcoma 10.1
18 uremic neuropathy 10.1 KIT KITLG
19 novak syndrome 10.1 CSF3 ERBB2
20 posterior myocardial infarction 10.1 CDKN2A ERBB2
21 acute liver failure 10.1 EPO EPOR FLI1
22 long qt syndrome 10.1 EPO EPOR
23 kala-azar 1 10.1 EWSR1 FLI1 KIT KITLG
24 aortic aneurysm 10.1 CDK4 CDKN2A
25 animal phobia 10.1 EPO EWSR1
26 intestinal impaction 10.0 EPO EPOR KITLG
27 palmoplantar keratosis 10.0 CDK4 CDKN2A EWSR1
28 osteomyelitis 10.0 CDK4 RB1
29 multifocal osteogenic sarcoma 10.0 CDK4 CDKN2A KIT
30 drug-induced hepatitis 10.0 EPO EPOR FLI1 KITLG
31 occlusion precerebral artery 10.0 CDK4 CDKN2A KIT
32 mood disorder 10.0 KIT MTOR RB1
33 acute dacryoadenitis 10.0 CSF3 ERBB2 KIT KITLG
34 erythrocytosis, somatic 9.9 EPO EPOR KIT KITLG
35 interstitial lung disease 9.9 CDK4 CDKN2A CDKN2B
36 hyperphosphatasia with mental retardation syndrome 2 9.9 CDKN2A CDKN2B KITLG
37 lattice corneal dystrophy 9.9 CDKN2A CDKN2B ERBB2
38 glucosephosphate isomerase deficiency 9.9 CDK4 CDKN2A ERBB2 MTOR
39 melanoma metastasis 9.9 CDK4 CDKN2A MTOR
40 bone squamous cell carcinoma 9.9 CDKN2A RB1
41 hyperparathyroidism, neonatal 9.9 CSF3 EPO FAS KITLG
42 peroxisome biogenesis disorder 7a 9.9 CSF3 EPO KIT KITLG
43 dic in newborn 9.9 CSF3 EPO EPOR KITLG
44 thalassemia 9.9
45 vaginitis 9.9
46 perinephritis 9.9
47 pancreatitis 9.9
48 endocervicitis 9.9
49 meningitis 9.9
50 proctitis 9.9 CDKN2A ERBB2 KIT

Graphical network of the top 20 diseases related to Ewing's Family of Tumors:



Diseases related to Ewing's Family of Tumors

Symptoms & Phenotypes for Ewing's Family of Tumors

GenomeRNAi Phenotypes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.16 KIT
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.16 MTOR EWSR1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.16 MTOR
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.16 CDK4
5 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.16 EWSR1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.16 EWSR1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.16 EWSR1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.16 EWSR1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.16 EWSR1 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.16 KIT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.16 MTOR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.16 EWSR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.16 KIT
14 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.16 EWSR1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.16 CDK4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.16 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.16 KIT MTOR CDK4 EWSR1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.16 CDK4
19 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.16 EWSR1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.16 MTOR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.16 EWSR1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.16 MTOR CDK4 KIT
23 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.16 KIT
24 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.16 EWSR1 KIT
25 Increased transferrin (TF) endocytosis GR00363-A 9.32 FLI1 KIT KITLG MTOR CDK4 CDKN2A

MGI Mouse Phenotypes related to Ewing's Family of Tumors:

44 (show all 23)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 CDKN2A CDKN2B EPO EPOR ERBB2 FAS
2 cardiovascular system MP:0005385 10.35 CDK4 CDKN2A EPO EPOR ERBB2 FAS
3 hematopoietic system MP:0005397 10.35 CDK4 CDKN2A CDKN2B CSF3 EPO EPOR
4 immune system MP:0005387 10.33 CDK4 CDKN2A CDKN2B CSF3 EPO EPOR
5 homeostasis/metabolism MP:0005376 10.3 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2
6 embryo MP:0005380 10.29 EPO EPOR ERBB2 FLI1 KIT KITLG
7 endocrine/exocrine gland MP:0005379 10.28 CDK4 CDKN2A CDKN2B ERBB2 FAS FLI1
8 growth/size/body region MP:0005378 10.27 CDK4 CDKN2A EPOR ERBB2 FAS FLI1
9 mortality/aging MP:0010768 10.27 EPO EPOR ERBB2 FAS FLI1 KIT
10 integument MP:0010771 10.24 CDK4 CDKN2A CDKN2B CSF3 EPO ERBB2
11 liver/biliary system MP:0005370 10.16 CDK4 CDKN2A EPO EPOR FAS FLI1
12 digestive/alimentary MP:0005381 10.14 CDK4 CDKN2A ERBB2 FAS KIT KITLG
13 nervous system MP:0003631 10.13 FLI1 KIT KITLG MTOR RB1 CDK4
14 neoplasm MP:0002006 10.11 KIT KITLG RB1 CDK4 CDKN2A CDKN2B
15 muscle MP:0005369 10.08 CDK4 CDKN2A EPO ERBB2 FLI1 KIT
16 limbs/digits/tail MP:0005371 10 EPO ERBB2 FAS KIT KITLG RB1
17 normal MP:0002873 9.97 MTOR RB1 CDK4 EPO EPOR ERBB2
18 no phenotypic analysis MP:0003012 9.88 CDKN2A CDKN2B EPOR KIT MTOR RB1
19 pigmentation MP:0001186 9.8 CDK4 CDKN2A FAS KIT KITLG RB1
20 renal/urinary system MP:0005367 9.8 CDK4 CDKN2B CSF3 FAS KIT MTOR
21 reproductive system MP:0005389 9.76 CDK4 CDKN2A CDKN2B ERBB2 FAS KIT
22 respiratory system MP:0005388 9.56 EPO EPOR ERBB2 FAS KIT MTOR
23 skeleton MP:0005390 9.23 EPO ERBB2 FAS KIT KITLG MTOR

Drugs & Therapeutics for Ewing's Family of Tumors

Drugs for Ewing's Family of Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 302)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
2
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
3 Dolutegravir Approved Phase 4 1051375-16-6 54726191
4 Anti-HIV Agents Phase 4,Phase 2,Phase 1
5 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1
7 Antiviral Agents Phase 4,Phase 2,Phase 1
8
protease inhibitors Phase 4,Phase 2
9 HIV Protease Inhibitors Phase 4,Phase 2
10 HIV Integrase Inhibitors Phase 4
11 Cytochrome P-450 CYP3A Inhibitors Phase 4
12 Cytochrome P-450 Enzyme Inhibitors Phase 4
13 Integrase Inhibitors Phase 4
14
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
15
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
16
Etoposide Approved Phase 3,Phase 1,Phase 2 33419-42-0 36462
17
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
18
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
19
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
20
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
21
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
22
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
23
Mesna Approved Phase 3,Phase 1,Phase 2 3375-50-6 598
24
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
25
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
26
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
27
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
28
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
29
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
30
Idarubicin Approved Phase 3 58957-92-9 42890
31
Zoledronic acid Approved Phase 3,Phase 1 118072-93-8 68740
32
Cyproheptadine Approved Phase 3 129-03-3 2913
33
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
34
Cobalt Phase 3,Phase 2 7440-48-4 104729
35 Alkylating Agents Phase 3,Phase 2,Phase 1
36 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
37 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
38 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
39 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
40 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
41 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
42 Etoposide phosphate Phase 3,Phase 1,Phase 2
43 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
44 Protective Agents Phase 3,Phase 2,Phase 1
45 Isophosphamide mustard Phase 3,Phase 2,Phase 1
46 Liver Extracts Phase 3,Phase 2,Phase 1
47 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
48 Antimitotic Agents Phase 3,Phase 2,Phase 1
49 Antirheumatic Agents Phase 3,Phase 1,Phase 2
50 Antineoplastic Agents, Alkylating Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 255)
id Name Status NCT ID Phase
1 Dolutegravir and Darunavir Evaluation in Adults Failing Therapy Not yet recruiting NCT03017872 Phase 4
2 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3
3 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3
4 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3
5 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
6 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
7 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3
8 Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma Recruiting NCT02063022 Phase 3
9 Study in Localized and Disseminated Ewing Sarcoma Recruiting NCT00987636 Phase 3
10 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Recruiting NCT02306161 Phase 3
11 Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer Recruiting NCT02856048 Phase 2, Phase 3
12 Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma Recruiting NCT00876031 Phase 3
13 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3
14 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
15 Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients Withdrawn NCT01734863 Phase 3
16 Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma Withdrawn NCT00334867 Phase 3
17 Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas Unknown status NCT00998361 Phase 2
18 Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Unknown status NCT00180947 Phase 2
19 Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors Unknown status NCT00003515 Phase 2
20 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2
21 Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status NCT00084695 Phase 2
22 Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy Completed NCT01222767 Phase 2
23 Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor Completed NCT00062205 Phase 2
24 Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors Completed NCT00560235 Phase 1, Phase 2
25 Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors Completed NCT00070109 Phase 2
26 Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors Completed NCT00061893 Phase 2
27 Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma Completed NCT01583543 Phase 2
28 New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma Completed NCT00001335 Phase 2
29 Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma Completed NCT02546544 Phase 2
30 Aerosol L9-NC and Temozolomide in Ewing's Sarcoma Completed NCT00492141 Phase 1, Phase 2
31 Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma Completed NCT00276692 Phase 2
32 Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma Completed NCT00516295 Phase 2
33 Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma Completed NCT00470275 Phase 2
34 Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors Completed NCT00357396 Phase 2
35 Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor Completed NCT00002643 Phase 2
36 Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma Completed NCT00073983 Phase 2
37 Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone Completed NCT00006234 Phase 1, Phase 2
38 Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma Completed NCT00003667 Phase 2
39 Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor Completed NCT00055952 Phase 2
40 Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer Completed NCT00002466 Phase 2
41 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed NCT00668148 Phase 2
42 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2
43 QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors Completed NCT00563680 Phase 2
44 A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas Completed NCT00001566 Phase 2
45 A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas Completed NCT00001564 Phase 2
46 Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas Completed NCT00165139 Phase 2
47 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2
48 Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure Completed NCT01136499 Phase 2
49 A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone Completed NCT01288573 Phase 1, Phase 2
50 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2

Search NIH Clinical Center for Ewing's Family of Tumors

Genetic Tests for Ewing's Family of Tumors

Anatomical Context for Ewing's Family of Tumors

MalaCards organs/tissues related to Ewing's Family of Tumors:

39
Bone

Publications for Ewing's Family of Tumors

Articles related to Ewing's Family of Tumors:

(show all 13)
id Title Authors Year
1
High-dose chemotherapy and stem cell rescue for high-risk Ewing's family of tumors. ( 21342043 )
2011
2
Ewing's family of tumors of the sinonasal tract and maxillary bone. ( 21107767 )
2011
3
Immunophenotypic profile of biomarkers related to anti-apoptotic and neural development pathways in the Ewing's family of tumors (EFT) and their therapeutic implications. ( 17695539 )
2007
4
Prognostic and therapeutic targets in the Ewing's family of tumors (PROTHETS). ( 17163151 )
2006
5
Single center experience of treatment of Ewing's family of tumors in Japan. ( 16437346 )
2006
6
EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. ( 15930281 )
2005
7
High-dose therapy and stem-cell rescue for Ewing's family of tumors in second remission. ( 15781877 )
2005
8
Megatherapy and stem cell transplantation for Ewing's family of tumors: a critical review of current literature. ( 15125709 )
2004
9
Single center experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties. ( 12885818 )
2003
10
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. ( 12972518 )
2003
11
Ewing's family of tumors involving structures related to the central nervous system: a review. ( 10742406 )
2000
12
Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. ( 10458232 )
1999
13
Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. ( 9850016 )
1998

Variations for Ewing's Family of Tumors

Expression for Ewing's Family of Tumors

Search GEO for disease gene expression data for Ewing's Family of Tumors.

Pathways for Ewing's Family of Tumors

Pathways related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

(show all 39)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 CDK4 CDKN2A CDKN2B EPOR ERBB2 KIT
2
Show member pathways
13.54 CSF3 EPO EPOR ERBB2 FAS KIT
3
Show member pathways
13.53 CDK4 CDKN2A CDKN2B CSF3 EPOR ERBB2
4
Show member pathways
13.3 CSF3 EPOR ERBB2 FAS KIT KITLG
5
Show member pathways
13.04 CDK4 CDKN2A CDKN2B EPO MTOR RB1
6
Show member pathways
12.77 CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
7
Show member pathways
12.49 CDK4 CDKN2A CDKN2B RB1
8 12.46 FAS FLI1 KIT KITLG
9 12.36 CDK4 CDKN2A CDKN2B RB1
10
Show member pathways
12.3 CDK4 CDKN2A FAS RB1
11
Show member pathways
12.28 CDK4 CDKN2A CDKN2B RB1
12 12.2 CDK4 CDKN2A CDKN2B RB1
13 12.19 CDK4 CDKN2A CDKN2B KITLG RB1
14
Show member pathways
12.12 CDK4 CDKN2A CDKN2B RB1
15
Show member pathways
12.11 CSF3 EPO EPOR MTOR
16
Show member pathways
12.06 CDK4 ERBB2 MTOR RB1
17
Show member pathways
12.04 EPO EPOR KIT KITLG
18 12.03 CDK4 CSF3 EPO EPOR KIT KITLG
19 12 ERBB2 KIT KITLG
20
Show member pathways
11.97 CDK4 CDKN2A ERBB2 RB1
21 11.94 CDK4 CDKN2A FAS MTOR
22 11.87 CDKN2A MTOR RB1
23 11.87 CDK4 CDKN2A CDKN2B ERBB2 FAS KIT
24 11.85 CSF3 EPO KIT KITLG
25 11.83 EPO ERBB2 MTOR
26 11.8 CDK4 CDKN2A MTOR RB1
27 11.75 CDK4 CDKN2B RB1
28 11.68 CDKN2A ERBB2 FAS
29 11.64 CDK4 MTOR RB1
30 11.61 ERBB2 KIT MTOR
31 11.57 CDK4 CDKN2A ERBB2 RB1
32 11.54 CSF3 EPO EPOR KIT KITLG
33 11.48 CDKN2A FAS RB1
34 11.44 EPO KIT KITLG
35 11.4 CDK4 CDKN2B RB1
36 11.24 CSF3 EPO FLI1 KITLG
37 11.18 CDK4 CDKN2A CDKN2B
38 11.02 CDKN2A RB1
39 10.88 KIT KITLG

GO Terms for Ewing's Family of Tumors

Biological processes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

(show all 24)
id Name GO ID Score Top Affiliating Genes
1 regulation of transcription from RNA polymerase II promoter GO:0006357 9.89 EPO ERBB2 FLI1 KIT RB1
2 positive regulation of cell proliferation GO:0008284 9.85 CDK4 CSF3 EPO KIT KITLG
3 phosphatidylinositol phosphorylation GO:0046854 9.75 ERBB2 KIT KITLG
4 G1/S transition of mitotic cell cycle GO:0000082 9.73 CDK4 CDKN2A RB1
5 phosphorylation GO:0016310 9.73 CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.71 CSF3 KITLG MTOR
7 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.69 ERBB2 KIT KITLG
8 negative regulation of phosphorylation GO:0042326 9.62 CDKN2A CDKN2B
9 positive regulation of Ras protein signal transduction GO:0046579 9.61 EPO KITLG
10 response to hyperoxia GO:0055093 9.61 CDK4 EPO
11 positive regulation of translation GO:0045727 9.61 CDK4 ERBB2 MTOR
12 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.6 EPO KIT
13 megakaryocyte development GO:0035855 9.59 FLI1 KIT
14 embryonic hemopoiesis GO:0035162 9.58 KIT KITLG
15 hepatocyte apoptotic process GO:0097284 9.57 FAS RB1
16 positive regulation of transcription from RNA polymerase III promoter GO:0045945 9.55 ERBB2 MTOR
17 positive regulation of MAP kinase activity GO:0043406 9.54 ERBB2 KIT KITLG
18 somatic stem cell division GO:0048103 9.52 CDKN2A KIT
19 ectopic germ cell programmed cell death GO:0035234 9.48 KIT KITLG
20 cell cycle arrest GO:0007050 9.46 CDKN2A CDKN2B MTOR RB1
21 negative regulation of immature T cell proliferation in thymus GO:0033088 9.32 CDKN2A ERBB2
22 phosphatidylinositol-mediated signaling GO:0048015 9.26 ERBB2 KIT KITLG MTOR
23 erythropoietin-mediated signaling pathway GO:0038162 8.8 EPO EPOR KIT
24 signal transduction GO:0007165 10.01 CDK4 EPO EPOR ERBB2 FAS KIT

Molecular functions related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 EPOR ERBB2 EWSR1 FAS RB1
2 nucleotide binding GO:0000166 9.73 CDK4 ERBB2 KIT MTOR
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.54 ERBB2 KIT KITLG
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.26 CDKN2A CDKN2B
5 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.16 ERBB2 KIT
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.13 ERBB2 KIT KITLG
7 kinase activity GO:0016301 9.1 CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
8 protein binding GO:0005515 10.13 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2

Sources for Ewing's Family of Tumors

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....